As of Wednesday close, Twist Bioscience Corporation’s (NASDAQ:TWST) stock was down -$2.05, moving down -9.60 percent to $19.31. The average number of shares traded per day over the past five days has been 813,080 shares. 1 time new highs have been achieved over the past 5 days, with a -$3.29 fall in that time frame. In the last twenty days, the average volume was 1,152,460, while in the previous 50 days, it was 1,181,596.
Since last month, TWST stock retreated -23.01%. Shares of the company fell to $19.28 on 08/16/23, the lowest level in the past month. A 52-week high of $53.89 was reached on 02/02/23 after having rallying from a 52-week low of $11.46. Since the beginning of this year, TWST’s stock price has dropped by -18.90% or -$4.50, and marked a new high 9 times. However, the stock has declined by -64.17% since its 52-week high.
TWST stock investors should be aware that Twist Bioscience Corporation (TWST) stock had its last reported insider trading activity 99 days ago on May 10. Cho Dennis, the of the company, purchased of 10,000 shares for $13.20 on May 10. It resulted in a $132,000 investment by the insider. Starovasnik Melissa A. sold 1,732 shares at an average price of $26.45 on Feb 09. The insider now owns 11,340 shares following the transaction. On Feb 09, Director JOHANNESSEN JAN sold 1,732 shares at $26.45 apiece. The transaction was valued at $45,820.
Valuation Metrics
The stock’s beta is 1.28. Besides these, the trailing price-to-sales (P/S) ratio of 4.81, the price-to-book (PB) ratio of 1.67.
Financial Health
In the three months ended June 29, Twist Bioscience Corporation’s quick ratio stood at 5.60, while its current ratio was 6.10, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 38.60% percent. In the year ended June 29, EBITDA margin amounted to -104.33%, whereas operating margins totaled -93.20%. Based on annual data, TWST earned $84.23 million in gross profit and brought in $203.56 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -27.80%. Return on equity (ROE) for the past 12 months was -28.90%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. TWST’s revenue rose 11.97% to $60.18 million during the quarter, while net income inched up to $63.74 million. While analysts expected Twist Bioscience Corporation to report -$1.14 quarterly earnings, the actual figure was -$1.01 per share, beating the consensus estimate by 11.40%. During the quarter, the company generated -$52.29 million in EBITDA. The liabilities of Twist Bioscience Corporation were 152.78 million at the end of its most recent quarter ended June 29, and its total debt was $93.03 million. The value of shareholders’ equity is $57.4 million.
Technical Picture
This quick technical analysis looks at Twist Bioscience Corporation’s (TWST) price momentum. With a historical volatility rate of 83.18%, the RSI 9-day stood at 29.11% on 16 August.
With respect to its five-day moving average, the current Twist Bioscience Corporation price is down by -14.56% percent or -$3.29. At present, TWST shares trade -25.76% below its 20-day simple moving average and +20.84% percent above its 100-day simple moving average. However, the stock is currently trading approximately +19.27% above its SMA50 and -42.31% below its SMA200.
Stochastic coefficient K was 11.75% and Stochastic coefficient D was 19.91%, while ATR was 1.57. Given the Stochastic reading of 0.45% for the 14-day period, the RSI (14) reading has been calculated as 37.33%. As of today, the MACD Oscillator reading stands at -1.39, while the 14-day reading stands at -1.60.
Analyst Ratings
Scotiabank launched its rating on Twist Bioscience Corporation (NASDAQ: TWST) to a Sector outperform in a note to investors on January 05, 2023. Twist Bioscience Corporation (TWST) has been rated Overweight by analysts. According to 1 brokerage firm, TWST is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Twist Bioscience Corporation stock as buy, with 5 recommending it as overweight.
With a median target price of $26.50, the current consensus forecast for the stock is $19.00 – $33.00. Based on these forecasts, analysts predict Twist Bioscience Corporation (TWST) will achieve an average price target of $26.25.
